Patients who have tried and failed multiple diet programs, explored bariatric consultations, or used other GLP-1 medications without achieving their desired results often find renewed hope with tirzepatide
Most users at the full dose describe their appetite as fundamentally different from pre-treatment
may help some patients Antihistamines (meclizine, dimenhydrinate) Can cause sedation and anticholinergic effects
Further, whilst real barriers persist, available evidence has indeed corroborated the potential clinical utility of GLP-1 RAs in HF(5), with the most recent GLP-1 RA CVOT (Amplitude-O with once-weekly efpeglenatide) indicating a relative risk reduction for hospitalisation-requiring HF of at least 30% in people with type 2 diabetes ( Of note, the finding of a markedly greater benefit on HF of efpeglenatide amongst trial participants using SGLT2 inhibitors at enrolment in the AMPLITUDE-O CVOT highlights another important point (Lam et al., 2021)
Control Release 344, 289301